Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2010
Event: Entry into a Material Definitive Agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services.
Key Financial Metrics
This filing reports a specific contract award rather than periodic financial results. No revenue, profit, cash flow, margin, debt, or liquidity figures are provided in this document.
| Metric | Value |
|---|---|
| Total Contract Value (Maximum) | $186.6 million |
| Initial Two-Year Period Value | Approximately $51 million |
| Option Periods Value (3 periods) | Approximately $126 million |
| Optional Non-Clinical Studies Funding | Approximately $9 million |
Material Changes
The filing discloses the execution of a cost-plus-fixed-fee development contract for a recombinant protective antigen (rPA) anthrax vaccine. This represents a significant potential revenue stream contingent upon the exercise of option periods and the completion of specific milestones.
Outlook, Risks, and Management Commentary
- Contract Structure: The agreement includes a base period of performance from September 19, 2010, to September 18, 2012. Three option periods may extend the performance through September 18, 2015.
- Key Activities: Initial activities include process characterization, assay validation, formulation, and stability studies.
- Milestones: Future funding is tied to milestones such as the completion of a Phase II clinical study, non-clinical efficacy studies, process validation, and consistency lot manufacture.
- Risks/Contingencies: The full contract value is not guaranteed; the $126 million in option periods and $9 million in optional studies are contingent upon the government exercising these options and the company meeting performance milestones.
Investor Verification Checklist
- Verify the specific terms of the "cost plus fixed fee" structure to understand margin implications.
- Monitor the company's progress on the initial Phase II clinical study and non-clinical efficacy studies required to trigger option periods.
- Review the attached press release (Exhibit 99.1) for additional details on the strategic significance of the rPA anthrax vaccine.
- Assess the likelihood of the government exercising the three one-year option periods based on future budget cycles and regulatory needs.